Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

The objective was to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) in treating adults with COVID-19 at high-risk of developing severe COVID-19 who do not require supplemental oxygen, compared to no treatment, from the Spanish National Health System (NHS) perspective. A decision-tree for the first year followed by a two-state Markov model with annual cycles for a lifetime horizon was developed. A cohort of 1000 high-risk, symptomatic COVID-19 patients entered the decision-tree for each comparator, divided into hospitalized patients, considering their level of care, and outpatients, for whom only symptom duration was considered.

COVID-19 Patients Benefitting From Remdesivir for Improved Survival: A Neural Network-Based Approach.

Conflicting results from randomized trials regarding the efficacy of remdesivir for COVID-19 have been reported. We aimed to develop a neural network (NN) to identify COVID-19 patients who would derive the greatest survival benefit from remdesivir. This multicenter observational study included adults hospitalized for COVID-19 between February 2020 and February 2021.

A real-world investigation into prescribing patterns and effectiveness of ceftolozane/tazobactam among critically ill patients from SPECTRA.

Background: Ceftolozane/tazobactam (C/T) real-world use was examined in a global population of critical care patients treated in intensive care unit settings.

Methods: The Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA) is a multinational, retrospective observational study of 617 adults treated with C/T conducted between 2016 and 2020. Population-associated clinical, treatment-related, and microbiologic characteristics, resource utilization, and clinical outcomes were assessed in critical care patients.